Lv1
60 积分 2024-09-01 加入
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
18天前
已完结
PT2.10.01 Incidence and Severity of Interstitial Lung Disease Associated With Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis
1个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
1个月前
已关闭
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
1个月前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
Bioanalytical approaches to support the development of antibody-oligonucleotide conjugate (AOC) therapeutic proteins
2个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3个月前
已完结
皖公网安备34019202002308
